Retrograde vs Antegrade Nephrostomy for Kidney Stones

Recruiting in Palo Alto (17 mi)

Overseen by Nadeem N Dhanani, MD,MPH

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: The University of Texas Health Science Center, Houston

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to compare relevant clinical outcomes in patients requiring percutaneous nephrostomy for urolithiasis treatment between those who undergo an antegrade approach versus a retrograde approach and to determine which clinical characteristics predict success of lithotomy with anterograde or retrograde percutaneous nephrostomy approaches.

Research Team

Nadeem N Dhanani, MD,MPH

Principal Investigator

The University of Texas Health Science Center, Houston

Eligibility Criteria

This trial is for individuals with large kidney stones (>10 mm) located in the renal pelvis or upper ureter, as confirmed by CT scans. It's not suitable for those who've had previous stone removal from the same kidney, have a current kidney infection, are pregnant, or have an abnormally shaped kidney like Horseshoe or Ectopic kidneys.

Inclusion Criteria

I have kidney stones larger than 10 mm in my renal pelvis or ureter.

Exclusion Criteria

I have an abnormal kidney shape or position.

I am suspected to have a kidney infection.

Pregnancy

Treatment Details

Interventions

• Antegrade Nephrostomy (Device)
• Retrograde Nephrostomy (Device)

Trial Overview The study compares two techniques of creating a channel to reach and remove kidney stones: one where access is made going backwards (retrograde) into the urinary system versus another where access is made going forwards (antegrade). The goal is to see which method leads to better outcomes.

Participant Groups

Group I: Treatment (retrograde nephrostomy) Experimental Treatment 1 Intervention

Group II: Control Group ( antegrade nephrostomy) Active Control 1 Intervention

Who Is Running the Clinical Trial?

The University of Texas Health Science Center, Houston

Lead Sponsor

Trials

974

Recruited

361,000+

Dr. LaTanya Love

The University of Texas Health Science Center, Houston

Interim President

MD from UT Medical Branch in Galveston

Dr. Jagat Narula

The University of Texas Health Science Center, Houston

Chief Academic Officer since 2023

MD, PhD